VEGFR3/Flt-4 Antibody (54703) [Unconjugated]

VEGFR3/Flt-4 was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Mouse Anti-Human VEGFR3/Flt-4 Monoclonal Antibody (Catalog # MAB3491) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Product Discontinued

VEGFR3/Flt-4 Antibody (54703) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human VEGFR3/Flt‑4
  Tyr25-Ile776
  Accession # P35916
• Specificity: Detects human VEGFR3/Flt‑4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25‑30% cross‑reactivity with recombinant mouse VEGFR3 is observed and no cross-reactivity with recombinant human (rh) VEGFR1 or rhVEGFR2 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: FLT4
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 8-25 ug/mL
  • Immunohistochemistry 8-25 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR3/Flt-4 Antibody (54703) [Unconjugated]

• EC 2.7.10
• EC 2.7.10.1
• FLT4
• Flt-4
• fms-related tyrosine kinase 4
• LMPH1A
• PCLFLT41
• soluble VEGFR3 variant 1
• soluble VEGFR3 variant 2
• soluble VEGFR3 variant 3
• Tyrosine-protein kinase receptor FLT4
• vascular endothelial growth factor receptor 3
• VEGF R3
• VEGFR3
• VEGFR-3
• VEGFR3Fms-like tyrosine kinase 4

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGFR3 cDNA encodes a 1298 amino acid (aa) precursor with a 24 aa signal peptide. Mature VEGFR3 is composed of a 751 aa extracellular domain, a 22 aa transmembrane domain and a 482 aa cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt-4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR3/Flt-4 Antibody (MAB3491)(8)

Publications using MAB3491

• Mohanakrishnan, V;Sivaraj, KK;Jeong, HW;Bovay, E;Dharmalingam, B;Bixel, MG;Dinh, VV;Petkova, M;Paredes Ugarte, I;Kuo, YT;Gurusamy, M;Raftrey, B;Chu, NTL;Das, S;Rios Coronado, PE;Stehling, M;Sävendahl, L;Chagin, AS;Mäkinen, T;Red-Horse, K;Adams, RH; Specialized post-arterial capillaries facilitate adult bone remodelling Nature cell biology 2024-11-11 [PMID: 39528700] (Immunohistochemistry, Human)
• A Chakrabort, CK Scogin, K Rizwan, TS Morley, JM Rutkowski Characterizing Lymphangiogenesis and Concurrent Inflammation in Adipose Tissue in Response to VEGF-D Front Physiol, 2020-04-22;11(0):363. 2020-04-22 [PMID: 32390866] (IHC-P, Mouse)
• SM Seyed Jafa, C Wiedmer, S Cazzaniga, Ž Frangež, M Shafighi, H Beltramine, B Weber, HU Simon, RE Hunger Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis PLoS ONE, 2018-11-08;13(11):e0207019. 2018-11-08 [PMID: 30408085] (IHC-P, Human)
• L Goertz, SW Schneider, A Desch, FT Mayer, J Koett, K Nowak, I Karampinis, MK Bohlmann, V Umansky, AT Bauer Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis Oncotarget, 2016-10-18;7(42):68527-68545. 2016-10-18 [PMID: 27602496] (ICC, Human)
• Ling Xu, Martin Hausmann, Wolfgang Dietmaier, Silvia Kellermeier, Theresa Pesch, Manuela Stieber-Gunckel et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines BMC Cancer 12/1/2010 [PMID: 20565817]
• Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC, Hung MC, Kuo ML Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell, 2008-06-01;13(6):557-60. 2008-06-01 [PMID: 18538739] (Western Blot, Human)
• Ball SG, Shuttleworth CA, Kielty CM Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J. Cell Biol., 2007-04-30;177(3):489-500. 2007-04-30 [PMID: 17470632] (Flow Cytometry, Human)
• Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC, Kuo ML The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 2006-03-01;9(3):209-23. 2006-03-01 [PMID: 16530705] (IHC-P, Human)

Bioinformatics

• Gene Symbol: FLT4
• Uniprot:
  • P35916()